NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Regulatory Post-Marketing Surveillance of Xolair® for Chronic Rhinosinusitis With Nasal Polyps

CompletedN/A

Sponsor: Novartis Pharmaceuticals

Conditions: Chronic Rhinosinusitis With Nasal Polyps

Interventions: Xolair

Countries: South Korea

This study aims to evaluate the safety and effectiveness of Xolair® in patients with chronic rhinosinusitis with nasal polyps in routine clinical practice.

Eligibility overview

Sex: ALL

Age: 18 Years to 100 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Adults aged ≥18 years
2. Patients with CRSwNP who are not adequately controlled with conventional therapy (INCS)
3. Patients prescribed with Xolair® as per the locally approved label information.
4. Patients who provide written informed consent to participate in the study

Exclusion Criteria:

1. Patients who do not provide consent to participate in the study
2. Patients participating in other clinical trial
3. Contraindications listed in the locally approved label information of Xolair®

   * Hypersensitivity to the active ingredient or any other ingredient of Xolair®
   * Patients with myocardial infarction or history of myocardial infarction (pre-filled syringes only)

Locations (16)

Anyang-si, Gyeonggi-do, South Korea
Bundang Gu, Gyeonggi-do, South Korea
Uijeongbu-si, Gyeonggi-do, South Korea
Incheon, Korea, South Korea
Seoul, Korea, South Korea
Seoul, Korea, South Korea
Seoul, Korea, South Korea
Seoul, Korea, South Korea
Seoul, Yangcheon gu, South Korea
Daegu, South Korea
Gyeonggi-do, South Korea
Seoul, South Korea
Seoul, South Korea
Seoul, South Korea
Seoul, South Korea
Suwon, South Korea